Medivation (MDVN) and Astellas Pharma (ALPMY.PK) say the FDA has assigned a PDUFA action date of...

|By:, SA News Editor

Medivation (MDVN) and Astellas Pharma (ALPMY.PK) say the FDA has assigned a PDUFA action date of November 22 for the review of their New Drug Application for enzalutamide, an investigational agent for the potential treatment of prostate cancer. MDVN +0.6% AH.